Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Update

Protara Therapeutics, Inc. (NASDAQ:TARA) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 4,400,000 shares, a decline of 13.7% from the December 31st total of 5,100,000 shares. Based on an average daily volume of 2,270,000 shares, the days-to-cover ratio is currently 1.9 days.

Institutional Investors Weigh In On Protara Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in Protara Therapeutics in the third quarter worth approximately $60,000. Marshall Wace LLP acquired a new stake in Protara Therapeutics in the second quarter valued at $161,000. Renaissance Technologies LLC boosted its position in shares of Protara Therapeutics by 77.8% during the 2nd quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock worth $313,000 after acquiring an additional 65,800 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Protara Therapeutics by 21.0% during the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after acquiring an additional 29,514 shares in the last quarter. Finally, Oppenheimer & Co. Inc. lifted its stake in Protara Therapeutics by 40.8% during the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock worth $328,000 after purchasing an additional 51,944 shares during the last quarter. Institutional investors and hedge funds own 38.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research note on Friday, December 6th. Guggenheim reaffirmed a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a research report on Friday, December 6th.

Protara Therapeutics Stock Up 9.3 %

NASDAQ TARA traded up $0.42 during trading on Friday, hitting $4.92. The stock had a trading volume of 533,393 shares, compared to its average volume of 313,754. The company has a market capitalization of $101.50 million, a PE ratio of -1.74 and a beta of 1.56. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48. The firm has a 50 day moving average price of $4.95 and a 200 day moving average price of $3.08.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). On average, sell-side analysts anticipate that Protara Therapeutics will post -2.99 earnings per share for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.